A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

NCT07093814 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: VRT106

Sponsor

Guangzhou Virotech Pharmaceutical Co., Ltd.